Peptide Library

FDA-approved

Hormones & metabolism

Albiglutide

Evidence

FDA approved

Class

GLP-1 receptor agonist fused to albumin

/

Albiglutide

KEY TAKEAWAY

Albiglutide is a GLP-1 receptor agonist fused to human albumin so it lasts about a week. It was sold as Tanzeum. The FDA approved albiglutide (Tanzeum) in 2014. The manufacturer stopped selling it in 2018 for commercial reasons.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

GLP-1 receptor agonist fused to albumin

Approved for

Type 2 diabetes

Key fact

The FDA approved albiglutide (Tanzeum) in 2014. The manufacturer stopped selling it in 2018 for commercial reasons.

Route

Weekly subcutaneous injection

Evidence strength

FDA approved

What it is

What it is

Albiglutide is a GLP-1 receptor agonist fused to human albumin so it lasts about a week. It was sold as Tanzeum.

How it works

How it works

It activates GLP-1 receptors, which raises insulin release when blood sugar is high and slows stomach emptying.

Regulatory status

Regulatory status

The FDA approved albiglutide (Tanzeum) in 2014. The manufacturer stopped selling it in 2018 for commercial reasons.

What it is used for

What it is used for

Type 2 diabetes.

Side effects and risks

Side effects and risks

Nausea, diarrhea and injection-site reactions were common. The label carried a boxed warning about thyroid C-cell tumors seen in rodents.

Citations

Citations

U.S. FDA prescribing information for Albiglutide. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo